Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Inhale and Baxter pause for breath in collaboration:

This article was originally published in Clinica

Executive Summary

Inhale Therapeutic Systems and Baxter International are attempting to renegotiate their deal to develop Inhale's pulmonary drug delivery system. Just 18 months ago, Baxter announced that up to $80 million would be available to Inhale to cover development and trials, through milestone payments. At the time Baxter put in $20 million as equity investment. Inhale says that the scope of the agreement has increased and - as Inhale is in the middle of a public stock offering - it made the declaration that it is seeking a renegotiation.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT086483

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel